Literature DB >> 8436175

Human interleukin-5 induces staphylococcal A Cowan 1 strain-activated human B cells to secrete IgM.

J N Bertolini1, C J Sanderson, E M Benson.   

Abstract

Studies on the role of human interleukin (IL)-5 in B cell growth and differentiation have yielded conflicting results. To clarify this issue, we studied the role of purified recombinant IL-5 on activated human B cells which were depleted of T cells and adherent cells. Human IL-5 augments IgM secretion, but not IgG or IgA secretion of purified human B cells activated with staphylococcal A Cowan 1 strain (SAC). However, the period of B cell activation with SAC is critical for the B cell to respond to IL-5. After 24 h of SAC activation, human B cells are responsive to the IL-5 signal, but with longer periods of activation, IL-5 responsiveness diminishes. This may explain some of the previous conflicting results. The IgM enhancement was not seen when B cells were activated with pokeweed mitogen. In addition, human recombinant IL-4 synergized with IL-5 in augmenting IgM secretion by SAC-activated B cells, while IL-5 synergized with IL-2 to augment IgM, IgG and IgA secretion by SAC-activated B cells. As the purified IL-5 was derived from a COS-1 cell supernatant, and COS-1 cells secrete IL-6, we examined whether a polyclonal IL-6 antibody blocked the IgM-enhancing activity of IL-5. IL-6 antibody did not block the IL-5 enhancement of IgM secretion, but a monoclonal antibody to IL-5 inhibited the human IL-5 activity on human B cells. These results demonstrate that human IL-5 augments IgM secretion of SAC-activated human B-cells. In addition, this lymphokine synergizes with IL-4 and IL-2 in supporting Ig secretion.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8436175     DOI: 10.1002/eji.1830230215

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  5 in total

1.  Human nasopharyngeal-associated lymphoreticular tissues. Functional analysis of subepithelial and intraepithelial B and T cells from adenoids and tonsils.

Authors:  P N Boyaka; P F Wright; M Marinaro; H Kiyono; J E Johnson; R A Gonzales; M R Ikizler; J A Werkhaven; R J Jackson; K Fujihashi; S Di Fabio; H F Staats; J R McGhee
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

2.  A role for interleukin-5 in promoting increased immunoglobulin M at the site of disease in leprosy.

Authors:  Maria T Ochoa; Rosane Teles; Blake E Haas; Danny Zaghi; Huiying Li; Euzenir N Sarno; Thomas H Rea; Robert L Modlin; Delphine J Lee
Journal:  Immunology       Date:  2010-11       Impact factor: 7.397

3.  Interleukin-5 (IL-5) and IL-6 define two molecularly distinct pathways of B-cell differentiation.

Authors:  T D Randall; F E Lund; J W Brewer; C Aldridge; R Wall; R B Corley
Journal:  Mol Cell Biol       Date:  1993-07       Impact factor: 4.272

4.  Ovalbumin sensitization changes the inflammatory response to subsequent parainfluenza infection. Eosinophils mediate airway hyperresponsiveness, m(2) muscarinic receptor dysfunction, and antiviral effects.

Authors:  D J Adamko; B L Yost; G J Gleich; A D Fryer; D B Jacoby
Journal:  J Exp Med       Date:  1999-11-15       Impact factor: 14.307

5.  Interleukin-5 (IL-5) Therapy Prevents Allograft Rejection by Promoting CD4+CD25+ Ts2 Regulatory Cells That Are Antigen-Specific and Express IL-5 Receptor.

Authors:  Bruce M Hall; Rachael M Hall; Giang T Tran; Catherine M Robinson; Paul L Wilcox; Prateek K Rakesh; Chuanmin Wang; Alexandra F Sharland; Nirupama D Verma; Suzanne J Hodgkinson
Journal:  Front Immunol       Date:  2021-11-29       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.